Limits...
Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.

Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang X, Dou R, Chen H, Liu H, Qi X, Zhou X, Chen C - BMC Cancer (2015)

Bottom Line: The results were presented as staining intensity and positive staining cell rate.LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time dependent (p < 0.001).Inhibition of p-Akt and p-mTOR, in vitro, decreased tumor cell VEGF-C and VEGF-D significantly.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, China. yfychx@163.com.

ABSTRACT

Background: Lymphangiogenesis plays a significant role in metastasis and recurrence of gastric cancer. There is no report yet focusing on the modulation of VEGF pathway and lymphangiogenesis of gastric cancer by targeting Akt/mTOR pathway. This study aims to demonstrate the relationship between Akt/mTOR pathway and VEGF-C/-D in gastric cancer.

Methods: We collected surgically resected gastric adenocarcinoma specimens from 55 consented patients. Immunohistochemistry staining of p-Akt, p-mTOR, VEGF-C, VEGF-D were performed and scored by two independent pathologists. The results were presented as staining intensity and positive staining cell rate. We also measured lymphatic vessel density (LVD) by D2-40 staining. Different dosages of p-Akt inhibitor LY294002 (12.5 μM, 25 μM, 50 μM) and p-mTOR inhibitor Rapamycin (25 nM, 50 nM, 100 nM) were given to gastric cancer cell line SGC-7901 in vitro. The inhibition rate of cell growth was tested by MTT at 24 h, 48 h and 72 h, respectively and protein expressions of Akt, p-Akt, mTOR, p-mTOR, VEGF-C and VEGF-D were examined by Western blot.

Results: The positive staining rates of p-Akt, p-mTOR, VEGF-C and VEGF-D in 55 gastric cancer clinical specimens were 74.54%, 85.45%, 72.73% and 58.18%. p-Akt and p-mTOR were positively correlated with VEGF-C and VEGF-D (p < 0.01). The LVD increased with incremental tendency of staining intensity of p-Akt, p-mTOR, VEGF-C and VEGF-D. LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time dependent (p < 0.001). In addition, the protein expression of p-Akt and p-mTOR were positively correlated with that of VEGF-C and VEGF-D (p < 0.05).

Conclusions: The level of LVD in gastric cancer specimens was significant higher than that of normal gastric tissue and was positively correlated with p-Akt, p-mTOR, VEGF-C and VEGF-D. Inhibition of p-Akt and p-mTOR, in vitro, decreased tumor cell VEGF-C and VEGF-D significantly. Therefore, we concluded that lymphangiogenesis of gastric cancer might be related to Akt/mTOR-VEGF-C/VEGF-D axis.

No MeSH data available.


Related in: MedlinePlus

Inhibition of p-Akt and p-mTOR in SGC-7901 cells by LY294002 and Rapamycin. A: SGC-7901 cell growth with intervention of different time points and dosages of LY294002, B: SGC-7901 cell growth with intervention of different time points and dosages of Rapamycin, C: Effect of LY294002 (50 μM) and Rapamycin (100 nM) on Akt/mTOR pathway and VEGF-C/-D by Western blot.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4358729&req=5

Fig3: Inhibition of p-Akt and p-mTOR in SGC-7901 cells by LY294002 and Rapamycin. A: SGC-7901 cell growth with intervention of different time points and dosages of LY294002, B: SGC-7901 cell growth with intervention of different time points and dosages of Rapamycin, C: Effect of LY294002 (50 μM) and Rapamycin (100 nM) on Akt/mTOR pathway and VEGF-C/-D by Western blot.

Mentions: SGC-7901 cells were cultured with three different dosages of LY294002 for 24 h, 48 h and 72 h. According to MTT assay, SGC-7901 cell growth was curbed and the inhibition rate was significantly correlated with LY294002 dosage and action time (p < 0.001) (Figure 3A).Figure 3


Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.

Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang X, Dou R, Chen H, Liu H, Qi X, Zhou X, Chen C - BMC Cancer (2015)

Inhibition of p-Akt and p-mTOR in SGC-7901 cells by LY294002 and Rapamycin. A: SGC-7901 cell growth with intervention of different time points and dosages of LY294002, B: SGC-7901 cell growth with intervention of different time points and dosages of Rapamycin, C: Effect of LY294002 (50 μM) and Rapamycin (100 nM) on Akt/mTOR pathway and VEGF-C/-D by Western blot.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4358729&req=5

Fig3: Inhibition of p-Akt and p-mTOR in SGC-7901 cells by LY294002 and Rapamycin. A: SGC-7901 cell growth with intervention of different time points and dosages of LY294002, B: SGC-7901 cell growth with intervention of different time points and dosages of Rapamycin, C: Effect of LY294002 (50 μM) and Rapamycin (100 nM) on Akt/mTOR pathway and VEGF-C/-D by Western blot.
Mentions: SGC-7901 cells were cultured with three different dosages of LY294002 for 24 h, 48 h and 72 h. According to MTT assay, SGC-7901 cell growth was curbed and the inhibition rate was significantly correlated with LY294002 dosage and action time (p < 0.001) (Figure 3A).Figure 3

Bottom Line: The results were presented as staining intensity and positive staining cell rate.LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time dependent (p < 0.001).Inhibition of p-Akt and p-mTOR, in vitro, decreased tumor cell VEGF-C and VEGF-D significantly.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, China. yfychx@163.com.

ABSTRACT

Background: Lymphangiogenesis plays a significant role in metastasis and recurrence of gastric cancer. There is no report yet focusing on the modulation of VEGF pathway and lymphangiogenesis of gastric cancer by targeting Akt/mTOR pathway. This study aims to demonstrate the relationship between Akt/mTOR pathway and VEGF-C/-D in gastric cancer.

Methods: We collected surgically resected gastric adenocarcinoma specimens from 55 consented patients. Immunohistochemistry staining of p-Akt, p-mTOR, VEGF-C, VEGF-D were performed and scored by two independent pathologists. The results were presented as staining intensity and positive staining cell rate. We also measured lymphatic vessel density (LVD) by D2-40 staining. Different dosages of p-Akt inhibitor LY294002 (12.5 μM, 25 μM, 50 μM) and p-mTOR inhibitor Rapamycin (25 nM, 50 nM, 100 nM) were given to gastric cancer cell line SGC-7901 in vitro. The inhibition rate of cell growth was tested by MTT at 24 h, 48 h and 72 h, respectively and protein expressions of Akt, p-Akt, mTOR, p-mTOR, VEGF-C and VEGF-D were examined by Western blot.

Results: The positive staining rates of p-Akt, p-mTOR, VEGF-C and VEGF-D in 55 gastric cancer clinical specimens were 74.54%, 85.45%, 72.73% and 58.18%. p-Akt and p-mTOR were positively correlated with VEGF-C and VEGF-D (p < 0.01). The LVD increased with incremental tendency of staining intensity of p-Akt, p-mTOR, VEGF-C and VEGF-D. LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time dependent (p < 0.001). In addition, the protein expression of p-Akt and p-mTOR were positively correlated with that of VEGF-C and VEGF-D (p < 0.05).

Conclusions: The level of LVD in gastric cancer specimens was significant higher than that of normal gastric tissue and was positively correlated with p-Akt, p-mTOR, VEGF-C and VEGF-D. Inhibition of p-Akt and p-mTOR, in vitro, decreased tumor cell VEGF-C and VEGF-D significantly. Therefore, we concluded that lymphangiogenesis of gastric cancer might be related to Akt/mTOR-VEGF-C/VEGF-D axis.

No MeSH data available.


Related in: MedlinePlus